In vitro activity of ceftazidime-avibactam against clinical isolates of enterobacteriaceae and pseudomonas aeruginosa collected in Asia-pacific countries: Results from the INFORM global surveillance program, 2012 to 2015

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 7, 2018, Pages

  Karlowsky, James A ^a   Kazmierczak, Krystyna M ^a   Bouchillon, Samuel K ^a   De Jonge, Boudewijn L M ^b,c   Stone, Gregory G ^b,c   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

Asia pacific; Ceftazidime avibactam; Enterobacteriaceae; Gram negative; INFORM; Pseudomonas aeruginosa; Surveillance

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEMASE; CARBAPENEMASE GES; CARBAPENEMASE KPC; CARBAPENEMASE OXA 48 LIKE; CEFEPIME; CEFTAZIDIME; CEPHALOSPORINASE; COLISTIN; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; SERINE; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATE; BROTH DILUTION; CHINA; CITROBACTER; CITROBACTER AMALONATICUS; CITROBACTER BRAAKII; CITROBACTER FARMERI; CITROBACTER FREUNDII; CITROBACTER KOSERI; CITROBACTER SEDLAKII; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER ASBURIAE; ENTEROBACTER CLOACAE; ENTEROBACTER KOBEI; ENTEROBACTER LUDWIGII; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HONG KONG; IN VITRO STUDY; JAPAN; KLEBSIELLA; KLEBSIELLA OXYTOCA; KLEBSIELLA OZAENAE; KLEBSIELLA PNEUMONIAE; KLUYVERA; KLUYVERA ASCORBATA; MALAYSIA; MIC90; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NON-FERMENTING GRAM-NEGATIVE BACTERIUM; NONHUMAN; PHILIPPINES; PRIORITY JOURNAL; PROTEACEAE; PROTEUS MIRABILIS; PROTEUS PENNERI; PROTEUS VULGARIS; PROVIDENCIA; PROVIDENCIA ALCALIFACIENS; PROVIDENCIA RETTGERI; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; RAOULTELLA; RAOULTELLA ORNITHINOLYTICA; RAOULTELLA PLANTICOLA; SERRATIA; SERRATIA LIQUEFACIENS; SERRATIA MARCESCENS; SERRATIA RUBIDAEA; SOUTH KOREA; TAIWAN; THAILAND; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 85049023515     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02569-17     Document Type: Article

References (29)

1. de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. 2016. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60:3163–3169. https://doi.org/10.1128/AAC.03042-15.
2. Nichols WW, de Jonge BLM, Kazmierczak KM, Karlowsky JA, Sahm DF. 2016. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749. https://doi.org/10.1128/AAC.00220-16.
3. Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo R, Jacobs MR. 2015. Activities of ceftazidime, ceftaroline and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single -lactamases. Diagn Microbiol Infect Dis 82:65– 69. https://doi.org/10.1016/j.diagmicrobio.2015.02.003.
4. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60:4490–4500. https://doi.org/10.1128/AAC.00107-16.
5. Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF. 2016. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC -lactamase-producing Enterobacteriaceae collected in the INFORM global surveillance study from 2012 to 2014. Antimicrob Agents Chemother 60:2849–2857. https://doi.org/10.1128/AAC.02286-15.
6. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390 –394. https://doi.org/10.1128/AAC.00756-10.
7. Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. 2015. In vitro susceptibility of characterized -lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59:1789 –1793. https://doi.org/10.1128/AAC.04191-14.
8. Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN, Sader HS. 2017. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). Diagn Microbiol Infect Dis 88:177–183. https://doi.org/10.1016/j.diagmicrobio.2017.02.020.
9. Kiratisin P, Chongthaleong A, Yen Tan T, Lagamayo E, Roberts S, Garcia J, Davies T. 2012. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 39:311–316. https://doi.org/10.1016/j.ijantimicag.2012.01.002.
10. Mendes RE, Mendoza M, Banga Singh KK, Castanheira M, Bell JM, Turnidge JD, Lin SSF, Jones RN. 2013. Regional resistance surveillance program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother 57:5721–5726. https://doi.org/10.1128/AAC.01121-13.
11. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. 2016. Multi-year, multi-national survey of the incidence and global distribution of metallo--lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067–1078. https://doi.org/10.1128/AAC.02379-15.
12. Biedenbach D, Bouchillon S, Hackel M, Hoban D, Kazmierczak K, Hawser S, Badal R. 2015. Dissemination of NDM metallo--lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART Global Surveillance Study from 2008 to 2012. Antimicrob Agents Chemother 59: 826–830. https://doi.org/10.1128/AAC.03938-14.
13. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromo-somally encoded resistance mechanisms. Clin Microbiol Rev 22:582– 610. https://doi.org/10.1128/CMR.00040-09.
14. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2014. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis 80: 233–238. https://doi.org/10.1016/j.diagmicrobio.2014.07.005.
15. Sheng W-H, Badal RE, Hsueh P-R. 2013. Distribution of extended-spectrum -lactamases, AmpC -lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 57:2981–2988. https://doi.org/10.1128/AAC.00971-12.
16. Logan LK, Weinstein RA. 2017. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 215(Suppl 1):S28–S36. https://doi.org/10.1093/infdis/jiw282.
17. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of -lactamase-producing strains. Antimicrob Agents Chemother 59:3509–3517. https://doi.org/10.1128/AAC.00163-15.
18. Clinical and Laboratory Standards Institute. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing, 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Papp-Wallace KM, Winkler ML, Taracila MA, Bonomo RA. 2015. Variants of -lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother 59:3710–3717. https://doi.org/10.1128/AAC.04406-14.
20. Winkler ML, Papp-Wallace KM, Bonomo R. 2015. Activity of ceftazidime/ avibactam against isogenic strains of Escherichia coli containing KPC and SHV -lactamases with single amino acid substitutions in the -loop. J Antimicrob Chemother 70:2279 –2286. https://doi.org/10.1093/jac/dkv094.
21. Compain F, Arthur M. 2017. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the -lactamase KPC-2. Antimicrob Agents Chemother 61:e00451-17. https://doi.org/10.1128/AAC.00451-17.
22. KPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
23. Pagès J-M, Peslier S, Keating TA, Lavigne J-P, Nichols WW. 2016. The role of the outer membrane and porins in the susceptibility of -lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrobial Agents Chemother 60:1349–1359. https://doi.org/10.1128/AAC.01585-15.
24. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Allergan USA, Inc. 2018. Avycaz® (ceftazidime and avibactam) for injection, for intravenous use, prescribing information. Revised February. Allergan USA, Inc, Irvine, CA.
26. ® (tigecycline) injection, powder, lyophilized, for solution, prescribing information. Revised June. Pfizer Inc., Philadelphia, PA.
27. European Committee on Antimicrobial Susceptibility Testing. 2016. Break-point tables for interpretation of MICs and zone diameters. Version 6.1. http://www.eucast.org.
28. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
29. Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF. 2015. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013. Antimicrob Agents Chemother 59:3606 –3610. https://doi.org/10.1128/AAC.05186-14.